Advertisement

Topics

Search Results for "Mirrx Therapeutics"

04:43 EDT 28th September 2016 | BioPortfolio

Matching Channels

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...

KIACTA

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Matching News

Seres Therapeutics, Emulate collaborate to support development of novel microbiome therapeutics

Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.

BIND Therapeutics says Pfizer’s $40 million bid for its assets is the winner

US biotech firm BIND Therapeutics, a developer of targeted and programmable therapeutics called Accurins,…

BIND Therapeutics collaborates with Affilogic

BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BT...

Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters i...

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when...

CSE: 2016-0819 - Suspension - Pivotal Therapeutics Inc. (PVO)

TORONTO, ONTARIO -- (Marketwired) -- 08/17/16 -- Pivotal Therapeutics Inc. is in default of CSE requirements. Effective at market close, Pivotal Therapeutics, currently the subject of a Cease Trad...

Matching PubMed Articles

Injectable biomaterials: a perspective on the next wave of injectable therapeutics.

We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...

Response #2 to Immediate Intraocular Pressure Tendency Following Intravitreal Delivery of Dexamethasone Implant; Alagöz et al. J. Ocul. Pharmacol. Ther. 32:44-49, 2016.

Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications.

Pigmentation and Macular Degeneration: Is There a Role for GPR143?

Fit for the Eye: Aptamers in Ocular Disorders.

For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement